聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者外周血IL-32的表达水平及意义  

IL-32 expression in peripheral blood mononuclear cells of chronic hepatitis B virus-infected patients with PEG IFN-α-2a treated and its significance

作　　者：刘永萍 顾慧华 徐晶 郑燕 黄伟 赵春 刘雁 Liu Yongping;Gu Huihua;Xu Jing;Zheng Yan;Huang Wei;Zhao Chun;Liu Yan(Department of Hepatology,Xixi Hospital of Hangzhou,Hangzhou 310023,China)

机构地区：[1]杭州市西溪医院肝病科,310023

出　　处：《中华实验和临床病毒学杂志》2019年第1期79-82,共4页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的阐明经治疗的慢性乙型肝炎(chronic hepatitis B,CHB)患者外周血IL-32的表达水平,探讨IL-32水平与谷丙转氨酶(ALT)、谷草转氨酶(AST)、白蛋白(ALB)及HBV DNA载量的相关性。方法选择干扰素治疗CHB患者30例以及健康对照者30例,TRIzol法提取外周血单核细胞(peripheral blood mononuclear cells,PBMCs)总RNA,应用实时荧光定量PCR检测IL-32mRNA的表达水平,并与患者ALT、AST、ALB和HBV DNA进行统计学分析。结果干扰素治疗CHB患者外周血IL-32的mRNA表达水平显著低于健康对照者(P=0.000),且与血清ALT、AST呈正相关(P=0.035,P=0.032),与ALB和HBV DNA载量无相关性(P=0.856,P=0.580)。结论经干扰素治疗CHB患者IL-32mRNA表达水平显著降低,IL-32水平与肝脏炎症程度相关。Objective To investigate the expression level of IL-32 in peripheral blood mononuclear cells (PBMCs) and its correlation with serum biochemical indices of liver function test and HBV DNA load in chronic hepatitis B (CHB) patients with PEG IFN-α-2a treated.Methods Thirty CHB patients with PEG IFN-α-2a treated (CHB group) and thirty normal health donors (health group) were enrolled in the study.Total RNA in PBMCs was extracted by using TRIzol.Than IL-32 mRNA level was assayed by using Realtime PGR.The correlation between IL-32 and ALT,AST,TBIL,HBV DNA load was analyzed using pearson's correlation analysis,respectively.Results IL-32 expression level in CHB group was significantly lower than that of health group.Moreover,the difference between them was statistically significant (P = 0.000).IL-32 level was positively correlated with serum ALT and AST,respectively (P=0.035,P=0.032),but was not correlated with ALB and HBV DNA load (P=0.856,P=0.580).Conclusions IL-32 expression level was decreased in CHB patients with PEG IFN-α-2a Treated and was associated with the severity of inflammation.

关 键 词：白细胞介素-32 慢性乙型肝炎 聚乙二醇α-2a 肝脏 炎症 

分 类 号：R512.62[医药卫生—内科学]